Cargando…

Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy

Natalizumab, a highly effective therapy for relapsing-remitting multiple sclerosis, is associated with a risk of progressive multifocal leukoencephalopathy (PML). The objective of this analysis was to examine factors predicting survival in a large natalizumab-associated PML global population. Patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong-Si, Tuan, Gheuens, Sarah, Gangadharan, Amy, Wenten, Made, Philip, Jeffrey, McIninch, James, Datta, Shoibal, Richert, Nancy, Bozic, Carmen, Bloomgren, Gary, Richman, Sandra, Weber, Thomas, Clifford, David B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628054/ https://www.ncbi.nlm.nih.gov/pubmed/25771865 http://dx.doi.org/10.1007/s13365-015-0316-4

Ejemplares similares

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study
por: Friend, Susan, et al.
Publicado: (2016)

Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
por: Plavina, Tatiana, et al.
Publicado: (2014)

Natalizumab: Progressive multifocal leukoencephalopathy: case report
Publicado: (2021)

Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy
por: Lo Buono, Viviana, et al.
Publicado: (2022)

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
por: Perkins, Molly R., et al.
Publicado: (2012)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data
por: Bloomgren, Gary, et al.
Publicado: (2012)

Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis
por: Herold, Tina Rike, et al.
Publicado: (2012)

Natalizumab-associated Progressive Multifocal Leukoencephalopathy in Patients with Multiple Sclerosis: A Mini Review
por: Fayyaz, Muniba, et al.
Publicado: (2018)

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy
por: Metz, Imke, et al.
Publicado: (2011)

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
por: McGuigan, C, et al.
Publicado: (2016)

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
por: Dahlhaus, Stefanie, et al.
Publicado: (2013)

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry
por: Prosperini, Luca, et al.
Publicado: (2016)

Risk of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patient Treated With Natalizumab: A Systematic Review
por: Vivekanandan, Govinathan, et al.
Publicado: (2021)

Presymptomatic Diagnosis with MRI and Adequate Treatment Ameliorate the Outcome after Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
por: Lindå, Hans, et al.
Publicado: (2013)

Early Magnetic Resonance Detection of Natalizumab-Related Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Sclerosis
por: Manenti, Guglielmo, et al.
Publicado: (2013)

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
por: Sinnecker, Tim, et al.
Publicado: (2016)

Insight into Metabolic (1)H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions
por: Schneider, Ruth, et al.
Publicado: (2017)

Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML
por: Alleg, Manel, et al.
Publicado: (2020)

Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk
por: Hartung, Hans-Peter, et al.
Publicado: (2021)

Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
por: Zanghì, Aurora, et al.
Publicado: (2021)

M125. DISEASE PREVALENCE, COMORBID CONDITIONS, AND MEDICATION UTILIZATION AMONG PATIENTS WITH SCHIZOPHRENIA IN THE UNITED STATES
por: Roy, Brittany, et al.
Publicado: (2020)

Changes in Brain Volumes Are Relevant during Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: Lessons from a Case Report
por: De Masi, Roberto, et al.
Publicado: (2022)

Progressive Multifocal Leukoencephalopathy
por: Adang, Laura, et al.
Publicado: (2015)

Treatment of progressive multifocal leukoencephalopathy
por: Castle, Daniel, et al.
Publicado: (2019)

Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study
por: Pontillo, Giuseppe, et al.
Publicado: (2017)

Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing
por: Rempe, Torge, et al.
Publicado: (2020)

Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience
por: Perncezky, Julian, et al.
Publicado: (2022)

Progressive Multifocal Leukoencephalopathy in an Immunocompetent Patient?
por: Johansen, Krisztina K., et al.
Publicado: (2013)

Progressive multifocal leukoencephalopathy in an immunocompetent patient
por: van der Kolk, Nicolien M., et al.
Publicado: (2016)

Diagnostic delay in progressive multifocal leukoencephalopathy
por: Miskin, Dhanashri P., et al.
Publicado: (2016)

Progressive multifocal leukoencephalopathy in the absence of immunosuppression
por: Zucker, Benjamin E., et al.
Publicado: (2017)

Progressive Multifocal Leukoencephalopathy: Current Insights
por: Kartau, Marge, et al.
Publicado: (2019)

AIDS-related progressive multifocal leukoencephalopathy
por: Abrão, Carolina de Oliveira, et al.
Publicado: (2020)

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
por: Lambert, Nicolas, et al.
Publicado: (2022)

Advances in Treatment of Progressive Multifocal Leukoencephalopathy
por: Bernard‐Valnet, Raphaël, et al.
Publicado: (2021)

Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors
por: Boumaza, Xavier, et al.
Publicado: (2022)

Rituximab-Associated Inflammatory Progressive Multifocal Leukoencephalopathy
por: Punch, Chandra, et al.
Publicado: (2016)

Progressive multifocal leukoencephalopathy in non-HIV patient
por: Vieira, Diego Rosseman, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_007u6fsg0bi29fctopq3pl4rf2